Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study

por Ishida, Tadao, Ito, Shigeki, Tanaka, Junji, Uchiyama, Michihiro, Kawano, Yawara, Moreau, Philippe, Martin, Thomas, Risse, Marie-Laure, Tada, Keisuke, Suzuki, Kenshi, Ishizawa, Kenichi
Publicado 2022

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY

por Facon, Thierry, Moreau, Philippe, Špicka, Ivan, Suzuki, Kenshi, Yong, Kwee, Mikhael, Joseph, Fukao, Taro, Bisht, Kamlesh, Armstrong, Nicole, Macé, Sandrine, Risse, Marie-Laure, Martin, Thomas
Publicado 2023

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

por Koiwai, Kimiko, El‐Cheikh, Raouf, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean‐Baptiste, Veyrat‐Follet, Christine, Risse, Marie‐Laure, van de Velde, Helgi, Semiond, Dorothée, Nguyen, Laurent
Publicado 2021

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

por Moreau, Philippe, Perrot, Aurore, Dimopoulos, Meletios A., Martin, Thomas, Facon, Thierry, Eduardo Capra, Marcelo, Beksac, Meral, Armstrong, Nicole, Dubin, Franck, Macé, Sandrine, Risse, Marie-Laure, Tekle, Christina, Klippel, Zandra, Richardson, Paul
Publicado 2023

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

por Facon, Thierry, Moreau, Philippe, Martin, Thomas G., Spicka, Ivan, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaëlle, Schwab, Sandrine, Martinez, Gracia
Publicado 2022

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

por Capra, Marcelo, Martin, Thomas, Moreau, Philippe, Baker, Ross, Pour, Ludek, Min, Chang-Ki, Leleu, Xavier, Mohty, Mohamad, Segura, Marta Reinoso, Turgut, Mehmet, LeBlanc, Richard, Risse, Marie-Laure, Malinge, Laure, Schwab, Sandrine, Dimopoulos, Meletios
Publicado 2021

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

por Martin, Thomas, Mikhael, Joseph, Hajek, Roman, Kim, Kihyun, Suzuki, Kenshi, Hulin, Cyrille, Garg, Mamta, Quach, Hang, Sia, Hanlon, George, Anup, Konstantinova, Tatiana, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, van de Velde, Helgi, Moreau, Philippe
Publicado 2022

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis

por Spicka, Ivan, Moreau, Philippe, Martin, Thomas G., Facon, Thierry, Martinez, Gracia, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Risse, Marie‐Laure, Asset, Gaëlle, Macé, Sandrine, van de Velde, Helgi, Yong, Kwee
Publicado 2022

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

por Dimopoulos, Meletios A., Moreau, Philippe, Augustson, Bradley, Castro, Nelson, Pika, Tomas, Delimpasi, Sosana, De la Rubia, Javier, Maiolino, Angelo, Reiman, Tony, Martinez‐Lopez, Joaquin, Martin, Thomas, Mikhael, Joseph, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaelle, Marion, Sylvia, Hajek, Roman
Publicado 2022

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

por Harrison, Simon J., Perrot, Aurore, Alegre, Adrian, Simpson, David, Wang, Ming Chung, Spencer, Andrew, Delimpasi, Sosana, Hulin, Cyrille, Sunami, Kazutaka, Facon, Thierry, Vlummens, Philip, Yong, Kwee, Campana, Frank, Inchauspé, Marlène, Macé, Sandrine, Risse, Marie‐Laure, van de Velde, Helgi, Richardson, Paul
Publicado 2021

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

por Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, Moreau, Philippe
Publicado 2023

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

por Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, Moreau, Philippe
Publicado 2023